PDS Biotechnology Corporation Plans to Hold a Conference on June 8

PDS Biotechnology Corporation announced that they will host a company conference call on June 8, 2021, at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology Annual Meeting. A press release summarizing the abstract data was issued on May 20.

PDS Biotechnology Corporation is a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology.

During the call, the company will review data from the previously announced oral presentation from the National Cancer Institute-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers. After the presentation, the company has decided to have a question and answer session.The conference call is scheduled to begin at 8:00 am ET on Tuesday, June 8, 2021. Participants should dial 877-407-3088 or 201-389-0927 and mention PDS Biotechnology. A live webcast of the conference call will also be available at https://event.webcasts.com/starthere.jsp?ei=1467666&tp_key=7a66e126d4

Currently, the full abstract for #2501 is titled Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies, is available on the ASCO meeting website. A copy of PDS Biotechnology Corporation presentation will be available on June 8th on the scientific presentations and publications page of PDS Biotech’s website. The ones who are willing to take part in the conference can do the registration which is now open and a live webcast of the event will be available online in the investor relations section of the company’s website. A replay will be available on the company website for 90 days following the webcast